Taysha Gene Therapies broadened its partnership with Catalent, signing a commercial supply agreement for TSHA-102, its investigational gene therapy for Rett syn

BWB News TV • 2026-08-03 12:11 UTC • By Billy Odell Tucker-Robinson

Taysha Gene Therapies broadened its partnership with Catalent, signing a commercial supply agreement for TSHA-102, its investigational gene therapy for Rett syndrome. The deal extends a collaboration that began in 2020.

Share this article

𝕏 X / Twitter Facebook LinkedIn WhatsApp

📚 More from Billy’s World

📰 Banking With Billy News All breaking financial news & market analysis 📚 Banking With Billy Books Deep-dive books on every financial story 💬 Join the Community discord.gg/VHxwmR5j4Y 🎥 Banking With Billy on YouTube Live streams & market commentary

Banking With Billy News Network — bankingwithbilly.com
Discord: discord.gg/VHxwmR5j4Y • YouTube: @BankingWithBilly